The FDA approved a new infused specialty therapy last week, Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics, for the treatment of adult patients with relapsed or
We’ve ranted about the encroachment of hospital and health system owned specialty pharmacies more times that one can count. The growth of these organizations seemed
Last week the FDA approved a new specialty therapy, Jemperli (dostarlimab) from GlaxoSmithKline, for treating patients with recurrent or advanced endometrial cancer. Uterine cancers are
The article below details a new PSAO option for pharmacies, the ‘first’ PSAO for community-based specialty pharmacies from AmerisourceBergen named the Accelerate Specialty Network. Network
White bagging is back in the news and is increasingly being used by hospitals and health systems as a weapon to demonize emerging models for
So, when was the last time your company looked at its protocols to safeguard Protected Health Information (PHI)? You know, all that patient-specific information that
So, can you easily explain the differences between a chemically synthesized drug and a biologic?You might be surprised how difficult that has become. The article
We dog eared the article below some time ago but never got around to including it in a weekly Anton Rx Report. It is insightful
Patients on complex specialty therapies always have lots of questions. Lately they have been asking lots of questions about the Covid-19 vaccines and whether they
Curiouser and curiouser…….The pharmacy management rabbit hole seems to be getting curiouser by the day. The article below details a very new and provocative tactic
